{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:25:12Z","timestamp":1787682312076,"version":"build-2784847793"},"reference-count":226,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T00:00:00Z","timestamp":1674345600000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pbb.2021.173321","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T18:34:32Z","timestamp":1642271672000},"page":"173321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders"],"prefix":"10.1016","volume":"213","author":[{"given":"Jeffrey M.","family":"Witkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Biggerstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn M.","family":"Kivell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dishary","family":"Sharmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal P.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yeunus","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2021.173321_bb0005","first-page":"900","article-title":"Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety","volume":"13","author":"Adell","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0010","unstructured":"aetna.com (n.d.) Brexanolone (Zulresso) - Medical Clinical Policy Bulletins|Aetna. Available at: http:\/\/www.aetna.com\/cpb\/medical\/data\/900_999\/0951.html (Accessed April 22, 2021)."},{"key":"10.1016\/j.pbb.2021.173321_bb0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0020","doi-asserted-by":"crossref","first-page":"108333","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","article-title":"Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023","volume":"57","author":"Atack","year":"2009","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.109.157909","article-title":"Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans","volume":"332","author":"Atack","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0035","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0376-8716(03)00099-1","article-title":"Principles of drug abuse liability assessment in laboratory animals","volume":"70","author":"Ator","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2021.173321_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.109.158303","article-title":"Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2\/3 subtypes","volume":"332","author":"Ator","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0269881108089603","article-title":"A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety","volume":"23","author":"Bailey","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0050","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.1991.tb01747.x","article-title":"Drug abuse potential evaluation in animals","volume":"86","author":"Balster","year":"1991","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.pbb.2021.173321_bb0055","doi-asserted-by":"crossref","first-page":"112924","DOI":"10.1016\/j.ejmech.2020.112924","article-title":"An update into the medicinal chemistry of translocator protein (TSPO) ligands","volume":"209","author":"Barresi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02247357","article-title":"5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions","volume":"112","author":"Barrett","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0065","series-title":"Buspirone: Mechanisms and Clinical Aspects","first-page":"37","article-title":"Buspirone in animal models of anxiety","author":"Barrett","year":"1991"},{"key":"10.1016\/j.pbb.2021.173321_bb0070","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1042\/bj0321957","article-title":"The isolation of progesterone and 3:20-allopregnanolone from ox adrenals","volume":"32","author":"Beall","year":"1938","journal-title":"Biochem. J."},{"key":"10.1016\/j.pbb.2021.173321_bb0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0091-3057(98)00180-4","article-title":"Effects of chronic antidepressants in an operant conflict procedure of anxiety in the rat","volume":"62","author":"Beaufour","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb0080","first-page":"1108","article-title":"Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms?","volume":"2","author":"Belzung","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0085","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/npp.2013.342","article-title":"Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?","volume":"39","author":"Belzung","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0090","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/acer.14000","article-title":"GABAA receptor subtypes and the abuse-related effects of ethanol in Rhesus monkeys: experiments with selective positive allosteric modulators","volume":"43","author":"Berro","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pbb.2021.173321_bb0095","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrd.2016.88","article-title":"Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets","volume":"15","author":"Bespalov","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbb.2021.173321_bb0100","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/epi.14555","article-title":"Progress report on new antiepileptic drugs: a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development","volume":"59","author":"Bialer","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0105","doi-asserted-by":"crossref","first-page":"172996","DOI":"10.1016\/j.pbb.2020.172996","article-title":"The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","volume":"196","author":"Biggerstaff","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.84","article-title":"Traumatic brain injuries","volume":"2","author":"Blennow","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/j.pbb.2021.173321_bb0115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1089\/neu.2011.1954","article-title":"Development of post-traumatic epilepsy after controlled cortical impact and lateral fluid-percussion-induced brain injury in the mouse","volume":"29","author":"Bolkvadze","year":"2012","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.pbb.2021.173321_bb0120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4522(98)00401-1","article-title":"Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy","volume":"89","author":"Bouilleret","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2021.173321_bb0125","series-title":"https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/345068","author":"Buhl","year":"2017"},{"key":"10.1016\/j.pbb.2021.173321_bb0130","doi-asserted-by":"crossref","first-page":"117277","DOI":"10.1016\/j.jns.2020.117277","article-title":"Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: a phase 2, open-label study","volume":"421","author":"Bullock","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/02791072.2013.825034","article-title":"Experienced drug users assess the relative harms and benefits of drugs: a web-based survey","volume":"45","author":"Carhart-Harris","year":"2013","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0140","series-title":"Curr Protoc Pharmacol Chapter 5:Unit 5.8","article-title":"Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice","author":"Castagn\u00e9","year":"2010"},{"key":"10.1016\/j.pbb.2021.173321_bb0145","article-title":"GABAkines \u2013 advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA RECEPTORS","volume":"108035","author":"Cerne","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1124\/jpet.104.081711","article-title":"Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists","volume":"313","author":"Chaki","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1527-3458.2005.tb00052.x","article-title":"ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety","volume":"11","author":"Chaki","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pbb.2021.173321_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488906775245318","article-title":"Non-monoamine-based approach for the treatment of depression and anxiety disorders","volume":"1","author":"Chaki","year":"2006","journal-title":"Recent Pat CNS Drug Discov"},{"key":"10.1016\/j.pbb.2021.173321_bb0165","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/bcp.12413","article-title":"The central nervous system effects of the partial GABA-A\u03b12,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males","volume":"78","author":"Chen","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/269342a0","article-title":"Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures","volume":"269","author":"Choi","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2021.173321_bb0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neuropharm.2018.11.031","article-title":"Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus","volume":"148","author":"Chuang","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.119.261735","article-title":"Isobolographic analysis of antiseizure activity of the GABA type a receptor-modulating synthetic neurosteroids brexanolone and ganaxolone with tiagabine and midazolam","volume":"372","author":"Chuang","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2016.12.009","article-title":"Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model","volume":"116","author":"Ciarlone","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0190","first-page":"430248","article-title":"A review of the updated pharmacophore for the alpha 5 GABA(a) benzodiazepine receptor model","volume":"2015","author":"Clayton","year":"2015","journal-title":"Int J Med Chem"},{"key":"10.1016\/j.pbb.2021.173321_bb0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ddr.430020205","article-title":"Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties","volume":"2","author":"Clineschmidt","year":"1982","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.pbb.2021.173321_bb0200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1176\/ajp.134.6.665","article-title":"Benzodiazepines: behavioral and neurochemical mechanisms","volume":"134","author":"Cook","year":"1977","journal-title":"AJP"},{"key":"10.1016\/j.pbb.2021.173321_bb0205","author":"Cook"},{"key":"10.1016\/j.pbb.2021.173321_bb0210","author":"Cook"},{"key":"10.1016\/j.pbb.2021.173321_bb0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbb.2021.173321_bb0220","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/arclin\/acx120","article-title":"The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis","volume":"33","author":"Crowe","year":"2018","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.pbb.2021.173321_bb0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1755-5949.2009.00109.x","article-title":"A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder","volume":"16","author":"Czobor","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pbb.2021.173321_bb0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbr.2007.10.023","article-title":"The microinjection of AMPA receptor antagonist into the accumbens shell, but not into the accumbens core, induces anxiolysis in an animal model of anxiety","volume":"188","author":"da Cunha","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2021.173321_bb0240","first-page":"pnab270","article-title":"Fewer opioids but more benzodiazepines? Prescription trends by specialty in response to the implementation of Michigan\u2019s Opioid Laws","author":"Danagoulian","year":"2021","journal-title":"Pain Med."},{"key":"10.1016\/j.pbb.2021.173321_bb0245","series-title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures (REALIZE Trial)","author":"Dandurand","year":"2021"},{"key":"10.1016\/j.pbb.2021.173321_bb0250","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"J Psychopharmacol (Oxford)"},{"key":"10.1016\/j.pbb.2021.173321_bb0255","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269881107082108","article-title":"Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers","volume":"22","author":"de Haas","year":"2008","journal-title":"J Psychopharmacol (Oxford)"},{"key":"10.1016\/j.pbb.2021.173321_bb0260","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0269881111415731","article-title":"The effects of TPA023, a GABAA\u03b12,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol","volume":"26","author":"de Haas","year":"2012","journal-title":"J Psychopharmacol (Oxford)"},{"key":"10.1016\/j.pbb.2021.173321_bb0265","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0270","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12887","article-title":"Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women: a pilot study","volume":"81","author":"Dichtel","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb0275","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0022-3565(25)12039-9","article-title":"Intrathecal baclofen and muscimol, but not midazolam, are antinociceptive using the rat-formalin model","volume":"275","author":"Dirig","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120473","article-title":"The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis","volume":"10","author":"do Rego","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2021.173321_bb0285","unstructured":"drugs.com (n.d.) List of 54 Anxiety Medications Compared. Drugs.com Available at: https:\/\/www.drugs.com\/condition\/anxiety.html [Accessed October 29, 2021]."},{"key":"10.1016\/j.pbb.2021.173321_bb0290","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0295","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cns.13046","article-title":"Pronounced antiepileptic activity of the subtype-selective GABAA-positive allosteric modulator PF-06372865 in the GAERS absence epilepsy model","volume":"25","author":"Duveau","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pbb.2021.173321_bb0300","series-title":"Eliem Therapeutics Reports Second Quarter Financial Results","author":"Eliem Therapeutics","year":"2021"},{"key":"10.1016\/j.pbb.2021.173321_bb0305","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(06)54001-3","article-title":"The role of GABA in the mediation and perception of pain","volume":"54","author":"Enna","year":"2006","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0315","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1523\/JNEUROSCI.2301-16.2016","article-title":"Functional synaptic integration of forebrain GABAergic precursors into the adult spinal cord","volume":"36","author":"Etlin","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2021.173321_bb0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/978160805159511001010156","article-title":"Vasopressin antagonists as anxiolytics and antidepressants: recent developments","volume":"1","author":"Fabio","year":"2010","journal-title":"Frontiers CNS Drug Discov"},{"key":"10.1016\/j.pbb.2021.173321_bb0325","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1528-1167.2009.02384.x","article-title":"A population-based study of risk of epilepsy after hospitalization for traumatic brain injury","volume":"51","author":"Ferguson","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0330","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.pbb.2021.173321_bb0335","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuropharm.2010.08.011","article-title":"Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure","volume":"59","author":"Fischer","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0340","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2017.03.001","article-title":"Pharmacological and antihyperalgesic properties of the novel \u03b12\/3 preferring GABAA receptor ligand MP-III-024","volume":"131","author":"Fischer","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2021.173321_bb0345","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-014-0189-8","article-title":"Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy","volume":"28","author":"Franco","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0350","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: current approaches and novel drug development","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0355","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(99)01318-8","article-title":"Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders","volume":"20","author":"Gasior","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0360","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0028-3908(99)00190-2","article-title":"Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate","volume":"39","author":"Gasior","year":"2000","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2021.173321_bb0365","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/jwh.2020.8483","article-title":"Brexanolone in postpartum depression: post hoc analyses to help inform clinical decision-making","volume":"30","author":"Gerbasi","year":"2021","journal-title":"J. Women's Health (Larchmt)"},{"key":"10.1016\/j.pbb.2021.173321_bb0370","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002130051118","article-title":"Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice","volume":"146","author":"Geter-Douglass","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0375","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABAA receptors: structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit","year":"2021","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.pbb.2021.173321_bb0380","series-title":"How We Know What Isn\u2019t So","author":"Gilovich","year":"1993"},{"key":"10.1016\/j.pbb.2021.173321_bb0385","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0014-4886(69)90128-9","article-title":"A permanent change in brain function resulting from daily electrical stimulation","volume":"25","author":"Goddard","year":"1969","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2021.173321_bb0390","doi-asserted-by":"crossref","first-page":"625233","DOI":"10.3389\/fphar.2021.625233","article-title":"8-Substituted triazolobenzodiazepines: in vitro and in vivo pharmacology in relation to structural docking at the \u03b11 subunit-containing GABAA receptor","volume":"12","author":"Golani","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0395","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"99","author":"Griebel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2021.173321_bb0400","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4088\/JCP.12m07804","article-title":"The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies","volume":"73","author":"Griebel","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb0405","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004714-199008000-00002","article-title":"Relative abuse liability of different benzodiazepines in drug abusers","volume":"10","author":"Griffiths","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11910-015-0545-1","article-title":"Glutamate and GABA imbalance following traumatic brain injury","volume":"15","author":"Guerriero","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.pbb.2021.173321_bb0420","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2021.173321_bb0425","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1007\/s00213-016-4369-8","article-title":"Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects","volume":"233","author":"Gunter","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0430","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/j.pain.0000000000001267","article-title":"A randomised, placebo-controlled clinical trial with the \u03b12\/3\/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain","volume":"159","author":"Gurrell","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2021.173321_bb0435","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1212\/WNL.0000000000007271","article-title":"Photosensitive epilepsy: robust clinical efficacy of a selective GABA potentiator","volume":"92","author":"Gurrell","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.pbb.2021.173321_bb0440","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/cpdd.912","article-title":"Safety, tolerability, and pharmacokinetics of multiple repeated oral doses of the \u03912\/3\/5-subtype selective GABAA -positive allosteric modulator PF-06372865 in healthy volunteers","volume":"10","author":"Gurrell","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pbb.2021.173321_bb0445","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(84)90197-3","article-title":"Effects of intrathecally administered THIP, baclofen and muscimol on nociceptive threshold","volume":"103","author":"Hammond","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00441-018-2973-0","article-title":"Animal models of depression: pros and cons","volume":"377","author":"Harro","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.pbb.2021.173321_bb0455","first-page":"131","article-title":"Pharmacophore\/receptor models for GABA(A)\/BzR alpha2beta3gamma2, alpha3beta3gamma2 and alpha4beta3gamma2 recombinant subtypes. Included volume analysis and comparison to alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2 subtypes","volume":"17","author":"He","year":"2000","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.pbb.2021.173321_bb0460","article-title":"Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders","volume":"5","author":"Hecking","year":"2021","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"10.1016\/j.pbb.2021.173321_bb0465","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/FBP.0b013e32832ec594","article-title":"Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils","volume":"20","author":"Heldt","year":"2009","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0470","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3565(24)37253-2","article-title":"Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors","volume":"284","author":"Helton","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0475","series-title":"Excitatory Amino Acids: Clinical Results With Antagonists","article-title":"2 D-CPPene (SDZ EAA-494)\u2014a competitive NMDA antagonist: pharmacology and results in humans","author":"Herrling","year":"1997"},{"key":"10.1016\/j.pbb.2021.173321_bb0480","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41467-018-05481-1","article-title":"Developmental seizures and mortality result from reducing GABAA receptor \u03b12-subunit interaction with collybistin","volume":"9","author":"Hines","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.pbb.2021.173321_bb0485","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2021.173321_bb0490","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pbb.2021.173321_bb0495","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1021\/jm980317y","volume":"41","author":"Huang","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0500","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/jm990341r","article-title":"Pharmacophore\/receptor models for GABAA\/BzR subtypes (\u03b11\u03b23\u03b32, \u03b15\u03b23\u03b32, and \u03b16\u03b23\u03b32) via a comprehensive ligand-mapping approach","volume":"43","author":"Huang","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0505","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0310057X1103900505","article-title":"Acute pain management in opioid-tolerant patients: a growing challenge","volume":"39","author":"Huxtable","year":"2011","journal-title":"Anaesth. Intensive Care"},{"key":"10.1016\/j.pbb.2021.173321_bb0510","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00213-016-4506-4","article-title":"GABAA receptor occupancy by subtype selective GABAA\u03b12,3 modulators: PET studies in humans","volume":"234","author":"Jucaite","year":"2017","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2021.173321_bb5015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(25)06888-7","article-title":"Tolerance to, and dependence on, some non-opiate psychotropic drugs","volume":"23","author":"Kalant","year":"1971","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2021.173321_bb0515","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(03)02086-7","article-title":"Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice","volume":"474","author":"Kaminski","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0520","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2021.173321_bb0525","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00952990.2021.1903479","article-title":"Biopsychosocial factors and health outcomes associated with cannabis, opioids and benzodiazepines use among older veterans","volume":"47","author":"Kang","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.pbb.2021.173321_bb0530","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuroscience.2017.01.021","article-title":"Neonatal bladder inflammation induces long-term visceral pain and altered responses of spinal neurons in adult rats","volume":"346","author":"Kannampalli","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2021.173321_bb0535","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0028-3908(97)00130-5","article-title":"Anxiolytic activity of glycine-B antagonists and partial agonists\u2014no relation to intrinsic activity in the patch clamp","volume":"36","author":"Karcz-Kubicha","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0540","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00213-018-4892-x","article-title":"Effect of ganaxolone in patients with posttraumatic stress disorder","volume":"235","author":"Kawada","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0545","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-015-4115-7","article-title":"Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism","volume":"233","author":"Kazdoba","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0550","article-title":"Anti-anxiety properties of selected medicinal plants","author":"Khan","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.pbb.2021.173321_bb0555","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-2654-5","article-title":"Shared structural mechanisms of general anaesthetics and benzodiazepines","volume":"585","author":"Kim","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2021.173321_bb0560","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2020.20020134","article-title":"Understanding the clinical effects and mechanisms of action of neurosteroids","volume":"178","author":"Kleinman","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb0565","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0091-3057(79)90125-4","article-title":"Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors","volume":"11","author":"Klepner","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb0570","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acschemneuro.0c00295","article-title":"Imidazodiazepine anticonvulsant, KRM-II-81, produces novel, non-diazepam-like antiseizure effects","volume":"11","author":"Knutson","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2021.173321_bb0575","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pbb.2008.02.019","article-title":"Novel discriminative stimulus effects of TPA023B, subtype-selective gamma-aminobutyric-acid(A)\/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023","volume":"90","author":"Kohut","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb0580","first-page":"471","article-title":"Comparative studies on antidepressant action of alprazolam in different animal models","volume":"38","author":"Kostowski","year":"1986","journal-title":"Pol. J. Pharmacol. Pharm."},{"key":"10.1016\/j.pbb.2021.173321_bb0585","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00213-021-05861-4","article-title":"The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study","volume":"238","author":"Lago","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187671","article-title":"Agomelatine, venlafaxine, and running exercise effectively prevent anxiety- and depression-like behaviors and memory impairment in restraint stressed rats","volume":"12","author":"Lapmanee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2021.173321_bb0595","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnsys.2013.00100","article-title":"A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study","volume":"7","author":"Lee","year":"2013","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.pbb.2021.173321_bb0600","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuropharm.2017.04.020","article-title":"Allopregnanolone decreases interictal spiking and fast ripples in an animal model of mesial temporal lobe epilepsy","volume":"121","author":"L\u00e9vesque","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0605","series-title":"Characterization of Novel \u03b12\/\u03b13 Subtype-Selective GABAA Receptor Positive Allosteric Modulators","author":"Lewter","year":"2019"},{"key":"10.1016\/j.pbb.2021.173321_bb0610","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschemneuro.6b00447","article-title":"Antinociceptive effects of a novel \u03b12\/\u03b13 subtype selective GABAA receptor positive allosteric modulator","volume":"8","author":"Lewter","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2021.173321_bb0615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2005.tb00034.x","article-title":"The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists","volume":"11","author":"Li","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pbb.2021.173321_bb0620","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.lfs.2005.08.002","article-title":"Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying","volume":"78","author":"Li","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0625","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1055\/s-0037-1610211","article-title":"Improved synthesis of anxiolytic, anticonvulsant, and antinociceptive \u03b12\/\u03b13-GABA(A)-ergic receptor subtype selective ligands as promising agents to treat anxiety, epilepsy, and neuropathic pain","volume":"50","author":"Li","year":"2018","journal-title":"Synthesis"},{"key":"10.1016\/j.pbb.2021.173321_bb0630","doi-asserted-by":"crossref","DOI":"10.1186\/s11689-017-9207-8","article-title":"A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome","volume":"9","author":"Ligsay","year":"2017","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.pbb.2021.173321_bb0635","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0091-3057(78)90368-4","article-title":"Relationship between benzodiazepine receptors and experimental anxiety in rats","volume":"9","author":"Lippa","year":"1978","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb0640","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/0024-3205(81)90498-7","article-title":"Differential ontogeny of type 1 and type 2 benzodiazepine receptors","volume":"28","author":"Lippa","year":"1981","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0645","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0024-3205(82)90001-7","article-title":"Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors","volume":"31","author":"Lippa","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0650","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2021.173321_bb0655","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1021\/jm950887n","article-title":"Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors","volume":"39","author":"Liu","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0660","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fncel.2017.00208","article-title":"Social isolation in early versus late adolescent mice is associated with persistent behavioral deficits that can be improved by neurosteroid-based treatment","volume":"11","author":"Locci","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pbb.2021.173321_bb0665","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs","volume":"47","author":"L\u00f6scher","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0670","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/epi4.12344","article-title":"Neurosteroid and benzodiazepine combination therapy reduces status epilepticus and long-term effects of whole-body sarin exposure in rats","volume":"4","author":"Lumley","year":"2019","journal-title":"Epilepsia Open"},{"issue":"16","key":"10.1016\/j.pbb.2021.173321_bb0675","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0024-3205(88)90589-9","article-title":"CNS depressants accelerate the dissociation of 35S-TBPS binding and GABA enhances their displacing potencies","volume":"43","author":"Maksay","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0680","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1021\/acs.jmedchem.9b01312","article-title":"Subtype selective \u03b3-aminobutyric acid type A receptor (GABAAR) modulators acting at the benzodiazepine binding site: an update","volume":"63","author":"Maramai","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0685","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-Hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-aminobutyric acid)A receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J. Med. Chem."},{"issue":"10152","key":"10.1016\/j.pbb.2021.173321_bb5010","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2021.173321_bb0690","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2016.05.029","article-title":"Self-administration of progesterone and synthetic neuroactive steroids by male rhesus monkeys","volume":"165","author":"Meng","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2021.173321_bb0695","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pbb.2018.04.009","article-title":"An antidepressant-related pharmacological signature for positive allosteric modulators of \u03b12\/3-containing GABAA receptors","volume":"170","author":"Methuku","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb0700","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/FBP.0000000000000464","article-title":"Effects of the \u03b12\/\u03b13-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam","volume":"30","author":"Moerke","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0705","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1126\/science.918669","article-title":"Benzodiazepine receptor: demonstration in the central nervous system","volume":"198","author":"M\u00f6hler","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.pbb.2021.173321_bb0710","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10408444.2021.1907303","article-title":"Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step?","volume":"51","author":"Moustafa","year":"2021","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.pbb.2021.173321_bb0715","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.STR.26.3.503","article-title":"Clinical experience with excitatory amino acid antagonist drugs","volume":"26","author":"Muir","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.pbb.2021.173321_bb0720","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0725","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s12035-018-1330-3","article-title":"Allopregnanolone treatment improves plasma metabolomic profile associated with GABA metabolism in fragile X-associated tremor\/ataxia syndrome: a pilot study","volume":"56","author":"Napoli","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2021.173321_bb0730","doi-asserted-by":"crossref","first-page":"548505","DOI":"10.3389\/fpsyt.2020.548505","article-title":"Glutamate systems in DSM-5 anxiety disorders: their role and a review of glutamate and GABA psychopharmacology","volume":"11","author":"Nasir","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb0735","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/pr.112.007419","article-title":"Intracranial self-stimulation to evaluate abuse potential of drugs","volume":"66","author":"Negus","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2021.173321_bb0740","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bph.14119","article-title":"Pharmacology in translation: the preclinical and early clinical profile of the novel \u03b12\/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865","volume":"175","author":"Nickolls","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0745","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1113\/JP277651","article-title":"Potentiating \u03b12 subunit containing perisomatic GABAA receptors protects against seizures in a mouse model of Dravet syndrome","volume":"597","author":"Nomura","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.pbb.2021.173321_bb0750","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/515165a","article-title":"Help luck along to find psychiatric medicines","volume":"515","author":"Nutt","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2021.173321_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2021.03.008","article-title":"Novel treatments for chronic pain: moving beyond opioids","volume":"234","author":"O\u2019Brien","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.pbb.2021.173321_bb0760","first-page":"5773","article-title":"Design and identification of a novel, functionally subtype selective GABAA positive allosteric modulator (PF-06372865)","volume":"62","author":"Owen","year":"2019","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.pbb.2021.173321_bb5005","first-page":"213","article-title":"The benzodiazepine--GABA--chloride ionophore receptor complex: common site of minor tranquilizer action","volume":"16","author":"Paul","year":"1981","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb0765","series-title":"Inevitable Illusions: How Mistakes of Reason Rule Our Minds","author":"Piattelli-Palmarini","year":"1996"},{"key":"10.1016\/j.pbb.2021.173321_bb0770","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1111\/j.1528-1167.2007.01182.x","article-title":"Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy","volume":"48","author":"Pieribone","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0775","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158231","article-title":"Chronic posttraumatic epilepsy following neocortical undercut lesion in mice","volume":"11","author":"Ping","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2021.173321_bb0780","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel gamma-aminobutyric acid type A (GABAA) receptor ligand that combines outstanding metabolic stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0785","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF00498510","article-title":"A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone","volume":"321","author":"Polc","year":"1982","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0790","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.089839","article-title":"Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity","volume":"315","author":"Porter","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0795","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression","volume":"54","author":"Powell","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.pbb.2021.173321_bb0800","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0306-4522(85)90102-2","article-title":"Septal driving of hippocampal theta rhythm: role of gamma-aminobutyrate-benzodiazepine receptor complex in mediating effects of anxiolytics","volume":"16","author":"Quintero","year":"1985","journal-title":"Neuroscience."},{"key":"10.1016\/j.pbb.2021.173321_bb0805","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00213-021-05791-1","article-title":"Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at \u03b12GABAA and \u03b13GABAA receptors","volume":"238","author":"Rahman","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0810","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1528-1167.2010.02870.x","article-title":"Neurosteroids as endogenous regulators of seizure susceptibility and use in the treatment of epilepsy","volume":"51","author":"Reddy","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0815","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/epi.14693","article-title":"Extrasynaptic \u03b3-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures","volume":"60","author":"Reddy","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0820","first-page":"237","article-title":"The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type","volume":"22","author":"Reimherr","year":"1986","journal-title":"Psychopharmacol. Bull."},{"issue":"3","key":"10.1016\/j.pbb.2021.173321_bb0825","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(24)36535-8","article-title":"Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate","volume":"280","author":"Rho","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0830","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0306-4522(02)00064-7","article-title":"Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy","volume":"112","author":"Riban","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2021.173321_bb0835","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/jm801652d","article-title":"Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogs in mice and rat models","volume":"52","author":"Rivas","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2021.173321_bb0840","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0845","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.25008","article-title":"Brexanolone as adjunctive therapy in super-refractory status epilepticus","volume":"82","author":"Rosenthal","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.pbb.2021.173321_bb0850","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2010.09.002","article-title":"Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models","volume":"92","author":"Rowley","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.pbb.2021.173321_bb0855","series-title":"Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint","author":"Sage Therapeutics","year":"2021"},{"key":"10.1016\/j.pbb.2021.173321_bb0860","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.10.009","article-title":"PCDH19-related epilepsy syndrome: a comprehensive clinical review","volume":"105","author":"Samanta","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.pbb.2021.173321_bb0865","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/00000542-199811000-00005","article-title":"AMPA\/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans","volume":"89","author":"Sang","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pbb.2021.173321_bb0870","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0278-5846(91)90082-C","article-title":"Animal models of anxiety and the development of novel anxiolytic drugs","volume":"15","author":"Sanger","year":"1991","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb0875","unstructured":"Saniona (n.d.) Saniona Initiates Phase 1 Clinical Trial of SAN711|Saniona AB - Newsroom. Available at: https:\/\/news.saniona.com\/news-releases\/news-release-details\/saniona-initiates-phase-1-clinical-trial-san711\/ [Accessed October 29, 2021]."},{"key":"10.1016\/j.pbb.2021.173321_bb0880","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.118.252155","article-title":"Intravenously administered ganaxolone blocks diazepam-resistant lithium-pilocarpine-induced status epilepticus in rats: comparison with allopregnanolone","volume":"368","author":"Saporito","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0885","article-title":"Benzodiazepine misuse: an epidemic within a pandemic","volume":"13","author":"Sarangi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.pbb.2021.173321_bb0890","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb0895","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/13543784.2019.1680638","article-title":"Novel investigational therapeutics for generalized anxiety disorder (GAD)","volume":"28","author":"Schanzer","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.pbb.2021.173321_bb0900","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00213-017-4615-8","article-title":"Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats","volume":"234","author":"Schwienteck","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0905","doi-asserted-by":"crossref","first-page":"105002","DOI":"10.1016\/j.yrtph.2021.105002","article-title":"Preclinical screening for antidepressant activity - shifting focus away from the Forced Swim Test to the use of translational biomarkers","volume":"125","author":"Sewell","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0915","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/pr.117.014449","article-title":"International Union of Basic and Clinical Pharmacology. CVI: GABAA receptor subtype- and function-selective ligands: key issues in translation to humans","volume":"70","author":"Sieghart","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2021.173321_bb0920","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JCP.0000000000000997","volume":"39","author":"Simen","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0925","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","article-title":"Anxioselective anxiolytics: on a quest for the Holy Grail","volume":"33","author":"Skolnick","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb0930","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2021.173321_bb0935","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.3390\/ijerph18157964","article-title":"Evaluating the implementation of a multicomponent intervention consisting of education and feedback on reducing benzodiazepine prescriptions by general practitioners: BENZORED hybrid type I cluster randomized controlled trial","volume":"18","author":"Socias","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.pbb.2021.173321_bb0940","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.13705","article-title":"Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures","volume":"58","author":"Sperling","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0945","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","article-title":"Don\u2019t stress about CRF: assessing the translational failures of CRF1 antagonists","volume":"234","author":"Spierling","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb0950","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/266732a0","article-title":"Benzodiazepine receptors in rat brain","volume":"266","author":"Squires","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2021.173321_bb0955","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/epi.12234","article-title":"Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy","volume":"54","author":"Srivastava","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb0960","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies","volume":"35","author":"Strzelczyk","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.pbb.2021.173321_bb0965","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amepre.2021.01.025","article-title":"Comparison of dental benzodiazepine prescriptions from the U.S., England, and Australia from 2013 to 2018","volume":"61","author":"Teoh","year":"2021","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.pbb.2021.173321_bb0970","first-page":"CD009900","article-title":"Pharmacological treatments for preventing epilepsy following traumatic head injury","volume":"8","author":"Thompson","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pbb.2021.173321_bb0975","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/070674370505000702","article-title":"Listening to the past: history, psychiatry, and anxiety","volume":"50","author":"Tone","year":"2005","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pbb.2021.173321_bb0980","series-title":"The Age of Anxiety: A History of America\u2019s Turbulent Affair With Tranquilizers","author":"Tone","year":"2009"},{"key":"10.1016\/j.pbb.2021.173321_bb0990","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(91)90894-V","article-title":"1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models","volume":"203","author":"Trullas","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb0995","series-title":"The Biologics News and Reports Portal","author":"Ulrich","year":"2021"},{"key":"10.1016\/j.pbb.2021.173321_bb1000","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/acn3.408","article-title":"First-in-man allopregnanolone use in super-refractory status epilepticus","volume":"4","author":"Vaitkevicius","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.pbb.2021.173321_bb1005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-3565(24)38907-4","article-title":"Characterization of the anxiolytic properties of a novel neuroactive steroid, Co 2-6749 (GMA-839; WAY-141839; 3alpha, 21-dihydroxy-3beta-trifluoromethyl-19-nor-5beta-pregnan-20-one), a selective modulator of gamma-aminobutyric acid(A) receptors","volume":"295","author":"Vanover","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb1010","doi-asserted-by":"crossref","first-page":"107809","DOI":"10.1016\/j.neuropharm.2019.107809","article-title":"The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans","volume":"162","author":"Varn\u00e4s","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb1015","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s13311-017-0555-6","article-title":"Open-label allopregnanolone treatment of men with fragile X-associated tremor\/ataxia syndrome","volume":"14","author":"Wang","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pbb.2021.173321_bb1020","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/epi.14563","article-title":"Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs","volume":"59","author":"West","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb1025","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1517\/13543784.2013.803066","article-title":"Glutamate-based anxiolytic ligands in clinical trials","volume":"22","author":"Wiero\u0144ska","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"Suppl. 4","key":"10.1016\/j.pbb.2021.173321_bb1030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/epi.12296","article-title":"Issues related to development of new antiseizure treatments","volume":"54","author":"Wilcox","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.pbb.2021.173321_bb1035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0165-6147(90)90150-7","article-title":"The behavioral pharmacology of NMDA receptor antagonists","volume":"11","author":"Willetts","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2021.173321_bb1040","series-title":"Accidental Medical Discoveries: How Tenacity and Pure Dumb Luck Changed the World","author":"Winters","year":"2016"},{"key":"10.1016\/j.pbb.2021.173321_bb1045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1871527314666150130154757","article-title":"Commentary: obstacles to the discovery of medicines for psychiatric disorders in modern times","volume":"14","author":"Witkin","year":"2015","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.pbb.2021.173321_bb1050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36359-1","article-title":"Effects of strychnine-insensitive glycine receptor ligands in rats discriminating dizocilpine or phencyclidine from saline","volume":"280","author":"Witkin","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb1055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-3565(24)38191-1","article-title":"Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine","volume":"289","author":"Witkin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb1060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2017.04.009","article-title":"Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for \u03b12\/3-containing GABAA receptors","volume":"157","author":"Witkin","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb1065","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuropharm.2018.05.006","article-title":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy","volume":"137","author":"Witkin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2021.173321_bb1075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.02.013","article-title":"The \u03b12,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats","volume":"180","author":"Witkin","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb1080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.119.260968","article-title":"The positive allosteric modulator of \u03b12\/3-containing GABAA receptors, KRM-II-81, is active in pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury","volume":"372","author":"Witkin","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2021.173321_bb1085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0035-1558003","article-title":"Enhancing neurosteroid synthesis\u2014relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines","volume":"48","author":"Wolf","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2021.173321_bb1090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0031-6997(25)00468-5","article-title":"Benzodiazepines: use, abuse, and consequences","volume":"44","author":"Woods","year":"1992","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2021.173321_bb1095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0091-3057(94)00428-L","article-title":"Anticonflict effect of MK-801 in rats: time course and chronic treatment studies","volume":"51","author":"Xie","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2021.173321_bb1100","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2017.00246","article-title":"Ganaxolone: a new treatment for neonatal seizures","volume":"11","author":"Yawno","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pbb.2021.173321_bb1105","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2174\/1389450118666171117131151","article-title":"Vortioxetine treatment for anxiety disorder: a meta-analysis study","volume":"19","author":"Yee","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.pbb.2021.173321_bb1115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.apha.2014.11.007","article-title":"Restoring the spinal pain gate: GABA(A) receptors as targets for novel analgesics","volume":"73","author":"Zeilhofer","year":"2015","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2021.173321_bb1120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.psychres.2019.07.006","article-title":"Brexanolone for postpartum depression: a meta-analysis of randomized controlled studies","volume":"279","author":"Zheng","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2021.173321_bb1125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","article-title":"Structure of a human synaptic GABAA receptor","volume":"559","author":"Zhu","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pbb.2021.173321_bb1130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s13311-020-00985-5","article-title":"Intranasal allopregnanolone confers rapid seizure protection: evidence for direct nose-to-brain delivery","volume":"18","author":"Zolkowska","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pbb.2021.173321_bb1135","doi-asserted-by":"crossref","first-page":"100196","DOI":"10.1016\/j.ynstr.2019.100196","article-title":"Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond","volume":"11","author":"Zorumski","year":"2019","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.pbb.2021.173321_bb1140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0269881115620435","article-title":"NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects","volume":"30","author":"Zuiker","year":"2016","journal-title":"J Psychopharmacol (Oxford)"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721002203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305721002203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:42:26Z","timestamp":1758775346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305721002203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":226,"alternative-id":["S0091305721002203"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173321","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2021.173321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173321"}}